Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.

[1]  U. Germing,et al.  Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. , 2012, Leukemia research.

[2]  N. DiBella,et al.  24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients , 2011 .

[3]  P. Fenaux,et al.  Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry , 2011 .

[4]  M. Stratton,et al.  Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts , 2011 .

[5]  J. Lancet,et al.  Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes , 2011 .

[6]  A. Falanga,et al.  Activated FVII-Antithrombin Complex and Tissue Factor mRNA As Potential Markers of Severe Thrombo-Hemorrhagic Syndrome in APL Patients , 2011 .

[7]  J. Tisdale,et al.  Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. , 2011, Blood.

[8]  M. Sekeres,et al.  Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence , 2011, Current hematologic malignancy reports.

[9]  D. Steensma.  The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate , 2011, Current hematologic malignancy reports.

[10]  H. Leitch.  Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes , 2011, Drugs.

[11]  R. Wells,et al.  Iron Overload Accelerates Development of Leukaemia: Evidence From a Mouse Model , 2010 .

[12]  A. Ganser,et al.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.

[13]  D. Cilloni,et al.  Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging , 2010, Haematologica.

[14]  A. Stamatoullas,et al.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). , 2010, Leukemia research.

[15]  Philippe Dessen,et al.  Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia , 2010, The Journal of experimental medicine.

[16]  J. Vardiman,et al.  The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. , 2010, Chemico-biological interactions.

[17]  E. Yannaki,et al.  The Impact of Desferrioxamine Postallogeneic Hematopoietic Cell Transplantation in Relapse Incidence and Disease-Free Survival: A Retrospective Analysis , 2010, Transplantation.

[18]  A. Raptis,et al.  Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices , 2010, Transfusion.

[19]  V. Pullarkat.  Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? , 2009, Blood.

[20]  M. Cazzola,et al.  The Effects of Mitochondrial Ferritin Expression in Normal and Sideroblastic Erythropoiesis. , 2009 .

[21]  J. Serody,et al.  Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study. , 2009 .

[22]  J. Dick,et al.  Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. , 2009, Blood.

[23]  H. Kantarjian,et al.  Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. , 2009, The oncologist.

[24]  S. Okabe,et al.  The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1 , 2009, Cancer science.

[25]  L. Arenillas,et al.  Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome , 2008 .

[26]  R. Wells,et al.  Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML? , 2008 .

[27]  H. Ehrlich,et al.  Requirements for Co-Stimulation in T-Cell Dependent and T-Cell Independent Re-Stimulation of FVIII-Specific Memory B Cells , 2008 .

[28]  J. Bennett.  Consensus statement on iron overload in myelodysplastic syndromes , 2008, American journal of hematology.

[29]  Dominica H. C. Wong,et al.  Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy , 2008 .

[30]  E. Fibach,et al.  Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome , 2007, European journal of haematology.

[31]  D. Steensma,et al.  Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS). , 2007 .

[32]  D. Steensma,et al.  Neither Serum Ferritin Nor Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts. , 2007 .

[33]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Lübbert,et al.  Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1α that augments transcriptional activity of CCAAT/enhancer-binding protein-α , 2005, Leukemia.

[36]  J. Porter.  Practical management of iron overload , 2001, British journal of haematology.

[37]  A. Hoffbrand,et al.  Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.

[38]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[39]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[40]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[41]  N. Gattermann,et al.  Iron overload in MDS—pathophysiology, diagnosis, and complications , 2010, Annals of Hematology.

[42]  J. Bennett,et al.  The myelodysplastic syndromes: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[43]  P. Jarritt,et al.  Article title: Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major , 2004 .

[44]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[45]  A. Piga,et al.  Results of long-term iron-chelating therapy. , 1996, Acta haematologica.

[46]  C. Almici,et al.  Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy. , 1995, Haematologica.